The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma

Abstract

Despite significant developments in the treatment of multiple myeloma (MM) over the past decade, many patients still experience relapse due to resistance to antimyeloma therapies. Particularly in the relapsed/refractory setting, recent treatment advances have resulted in significantly improved prognosis for MM patients. Among novel therapeutic modalities, B-cell maturation antigen (BCMA)-directed immunotherapies, including chimeric antigen receptor (CAR) T-cell therapy, antibody-drug conjugates (ADCs) and bispecific T cell engagers (BiTEs), have achieved remarkable clinical response in patients with relapsed/ refractory MM (RRMM). This article discusses the recent progress in anti-BCMA targeted treatments for RRMM, with a focus on currently available agents.